Show simple item record

Prostate carcinoma presentation, diagnosis, and staging

dc.contributor.authorMiller, David C.en_US
dc.contributor.authorHafez, Khaled S.en_US
dc.contributor.authorStewart, Andrew K.en_US
dc.contributor.authorMontie, James E.en_US
dc.contributor.authorWei, John T.en_US
dc.date.accessioned2006-04-19T13:31:37Z
dc.date.available2006-04-19T13:31:37Z
dc.date.issued2003-09-15en_US
dc.identifier.citationMiller, David C.; Hafez, Khaled S.; Stewart, Andrew; Montie, James E.; Wei, John T. (2003)."Prostate carcinoma presentation, diagnosis, and staging." Cancer 98(6): 1169-1178. <http://hdl.handle.net/2027.42/34379>en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/34379
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12973840&dopt=citationen_US
dc.description.abstractBACKGROUND Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, diagnosis, and staging. METHODS The authors reviewed 54,212 cases from the 1998 PCE. Demographics, presenting signs and symptoms, tumor characteristics, prostate biopsy techniques, and use of staging modalities were evaluated. RESULTS The mean age of patients in the sample was 68 years. Among patients with available data, 87.5% had a prostate specific antigen (PSA) level of 4 ng/mL or higher, 83.1% had American Joint Committee on Cancer (AJCC) Stage I–II lesions, 80.2% had well or moderately differentiated cancers, and 68.7% of newly diagnosed patients were asymptomatic. Compared with symptomatic patients, asymptomatic patients were more likely to have localized disease (84.6% vs. 78.2%, P < 0.01) and well or moderately differentiated tumors (82.2% vs. 74.6%, P < 0.01). Transrectal ultrasound-guided prostate biopsy was the most common method of tissue confirmation (45.4%). Radionuclide bone scintigraphy was the most frequently employed staging modality (48.7%). Use of various staging evaluations was more frequent among patients at increased risk for disseminated disease (PSA > 10 ng/mL and/or high-grade tumors) versus patients at lower risk (PSA ≤ 10 and low to moderate-grade tumors) for metastatic disease ( P < 0.005). CONCLUSIONS Most newly diagnosed patients with prostate carcinoma are asymptomatic and have moderately differentiated and organ-confined disease. Compared with symptomatic patients, tumors in asymptomatic men are associated with lower pretreatment PSA levels, AJCC stage, and tumor grade. Selective use of staging evaluations, based on risk of metastatic disease, may be relatively uncommon. The NCDB remains a unique and rich source of novel patient care information and serves as a national point of reference for prostate carcinoma presentation, diagnosis, and staging. Cancer 2003;98:1169–78. © 2003 American Cancer Society. DOI 10.1002/cncr.11635en_US
dc.format.extent105539 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherCancer Research, Oncology and Pathologyen_US
dc.titleProstate carcinoma presentation, diagnosis, and stagingen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Urology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Urology, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Urology, University of Michigan, Ann Arbor, Michigan ; Dr. Montie has a financial and/or other relationship with Astra Zeneca and UroCor.en_US
dc.contributor.affiliationumDepartment of Urology, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 936-9127 ; Department of Urology, Taubman Health Care Center, University of Michigan Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330en_US
dc.contributor.affiliationotherCommission on Cancer, American College of Surgeons, Chicago, Illinoisen_US
dc.identifier.pmid12973840en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/34379/1/11635_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.11635en_US
dc.identifier.sourceCanceren_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.